Want to see BNR full AI Analyst Report?
BNR Stock Chart & Stats
$10.44
$0.45(5.03%)
At close: 4:00 PM EDT
$10.44
$0.45(5.03%)
Day’s Range― - ―
52-Week Range$6.79 - $41.72
Previous Close$9.27
Volume457.00
Average Volume (3M)6.82K
Market Cap
$99.40M
Enterprise Value$112.09
Total Cash (Recent Filing)$446.00M
Total Debt (Recent Filing)$50.86M
Price to Earnings (P/E)―
Beta1.87
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-56.30
Shares Outstanding8,813,858
10 Day Avg. Volume7,693
30 Day Avg. Volume6,823
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.28
Price to Sales (P/S)0.28
P/FCF Ratio-4.51
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Gross MarginsA consistently high gross margin gives Burning Rock room to fund laboratories, testing platforms and research capabilities. It also provides operating leverage if testing volumes recover, supporting future profitability despite current losses.
Conservative LeverageVery low leverage limits interest and refinancing risk while preserving financial flexibility. This is valuable for a diagnostics company investing in clinical infrastructure and pharmaceutical services during an uneven revenue period.
Improving Cost DisciplineExpense reductions and materially lower historical losses show management is adapting its cost base to weaker demand. Sustained discipline could extend liquidity and narrow the path toward breakeven as newer testing channels develop.
Bears Say
Declining RevenuePersistent top-line contraction weakens operating leverage and limits the resources available for technology development and commercial expansion. Recovery depends on converting the in-hospital strategy and stabilizing pharmaceutical project activity.
Negative Cash GenerationThe business remains dependent on existing liquidity or future financing because operations do not yet fund investment and overhead. Continued cash consumption could constrain growth initiatives and increase dilution or funding risk.
Unprofitable OperationsLack of sustainable earnings indicates that strong gross margins have not yet covered operating costs. A wider quarterly loss raises execution risk and makes the company more vulnerable to delays in volume growth or project delivery.
Burning Rock Biotech News
BNR FAQ
What was Burning Rock Biotech Ltd.’s price range in the past 12 months?
Burning Rock Biotech Ltd. lowest stock price was $6.79 and its highest was $41.72 in the past 12 months.
What is Burning Rock Biotech Ltd.’s market cap?
Burning Rock Biotech Ltd.’s market cap is $99.40M.
When is Burning Rock Biotech Ltd.’s upcoming earnings report date?
Burning Rock Biotech Ltd.’s upcoming earnings report date is Sep 02, 2026 which is today.
How were Burning Rock Biotech Ltd.’s earnings last quarter?
Burning Rock Biotech Ltd. released its earnings results on Jun 09, 2026. The company reported -$0.24 earnings per share for the quarter.
Is Burning Rock Biotech Ltd. overvalued?
According to Wall Street analysts Burning Rock Biotech Ltd.’s price is currently Overvalued.
Does Burning Rock Biotech Ltd. pay dividends?
Burning Rock Biotech Ltd. does not currently pay dividends.
What is Burning Rock Biotech Ltd.’s EPS estimate?
Burning Rock Biotech Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Burning Rock Biotech Ltd. have?
Burning Rock Biotech Ltd. has 8,813,858 shares outstanding.
What happened to Burning Rock Biotech Ltd.’s price movement after its last earnings report?
Burning Rock Biotech Ltd. reported an EPS of -$0.24 in its last earnings report. Following the earnings report the stock price went down -9.813%.
Which hedge fund is a major shareholder of Burning Rock Biotech Ltd.?
Currently, no hedge funds are holding shares in BNR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Burning Rock Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
6.09%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-3.25%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Burning Rock Biotech Ltd.
Headquartered in Guangzhou, China, and established in 2014, Burning Rock Biotech Limited is primarily engaged in developing and providing diagnostic solutions for cancer therapy selection within the People's Republic of China. Its operations are structured across three key segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company leverages next-generation sequencing (NGS) technology to offer a diverse portfolio of tests designed to guide therapeutic decisions and predict prognoses for a wide array of cancer types. These include, but are not limited to, lung, gastrointestinal, prostate, breast, lymphomas, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. These analyses can be performed on both tissue and liquid biopsy samples. Burning Rock's flagship products encompass OncoCompass IO, a liquid biopsy test; OncoScreen IO, a comprehensive pan-cancer test for tissue samples; OncoCompass Target, a circulating tumor DNA (ctDNA) liquid biopsy-based test specifically for non-small cell lung cancer (NSCLC); ColonCore, which assesses microsatellite instability (MSI) and identifies genetic mutations relevant to gastrointestinal cancers; and the OncoScreen ParpMatch and OncoCompass ParpMatch tests, which target genes critical for homologous recombination deficiency. To further enhance its offerings, the company has entered into strategic agreements, including a development and commercialization license with Myriad Genetics, Inc. for Myriad myChoice tumor testing in China, and a licensing agreement with Oncocyte Corporation for DetermaRx, a risk stratification test for early-stage lung cancer patients, also for the Chinese market. Burning Rock also actively collaborates on clinical trials and research studies with a notable roster of pharmaceutical and biotech partners, such as AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA.